Primary cutaneous marginal zone B-cell lymphoma with amyloid deposition: report of two cases with review of literature.
OBJECTIVE
Amyloid deposition is rare. If there was a great amount of amyloid depositions in the skin tissue, it would be considered to be amyloid deposition disease at first, and then primary cutaneous marginal zone B-cell lymphoma (PCMZL). This study was to analyze the diagnosis and differential diagnosis of two cases of PCMZL with amyloid deposition.


METHODS
Clinicopathologic characteristics and follow-up of two cases of PCMZL were analyzed. Immunohistochemical staining was performed by EnVision method using antibodies LCA, CD19, CD20, CD79a, CD3, CD7, MUM1, kappa, lambda, Ki-67. IgH and TCRgamma gene rearrangement was detected by polymerase chain reactive (PCR).


RESULTS
Case 1, a 71-year-old Chinese male, had a subcutaneous mass on the right elbow that was initially diagnosed with "amyloidosis" in 2004. Three years after the initial diagnosis, he developed recurrences on the right para-auxillary that was still diagnosed with "probably amyloidosis". Four years after the first diagnosis, the patient presented a lesion on the right para-auxillary with a diameter of 2 cm and a lesion on the temporal-parietal dural with a size of 6.0 cmx3.0 cmx3.0 cm. Case 2, a 68-year-old Chinese male, had a subcutaneous mass next to back of the left ear with a size of 9.0 cmx5.0 cm, and he underwent a operation one year previously because of subcutaneous mass in the same site. Microscopically, the tumors of both cases were located in dermis and subcutaneous, tumor cells were medium size with a nodular or diffuse distribution, and some of tumor cells were plasmacytoid/plasma cells. Morphologically, the temporal-parietal dural lesion was similar to subcutaneous lesion and infiltrated into cranial (case 1). Juxtaposed the tumor cells of two cases, there were the large amyloid deposits of amorphous hyaline material and concentrically laminated hyaline spherules in case 1, while cord-like amyloid deposits in case 2. Reactive lymphoid follicles with germinal centers and foreign body giant cells in the stroma were found surrounding the amyloid deposits. Congo red staining showed positive of amyloid deposition in tumor tissues of both cases. Immunohistochemical staining revealed that LCA, CD19, CD20, CD79a and MUM1 expressions were positive in tumor cells, and Ki-67 expression was about 8%-10%. IgL restricted expression as kappa positive while lambda negative was found in both cases. PCR results showed monoclone gene rearrangement of IgH gene in both cases.


CONCLUSIONS
Our findings suggest that amyloid deposition rarely present in both primary and metastatic tumors in PCMZL, and its diagnosis should be considered to avoid misdiagnosis. The patients with PCMZL should undergo regular examinations and chemotherapy as well as a long-term follow-up since it is apt to recur or relapse.
Zhang
Hai-Yan
HY
Department of Pathology, Nanyang Medical School of Henan Province, Nanyang, Henan 473000, PR China.
Liu
An-Li
AL
Zhou
Ling-sheng
LS
He
Miao-Xia
MX
Wang
Jian-Xin
JX
D000368:Aged; D000686:Amyloidosis / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D015703:Antigens, CD / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000627:therapeutic use; D004550:Elbow; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D006801:Humans; D050835:Interferon Regulatory Factors / Q000378:metabolism; D017493:Leukocyte Common Antigens / Q000378:metabolism; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local; D011241:Prednisone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D014750:Vincristine / Q000627:therapeutic use; D000099218:Interferon Regulatory Factor-4
D015703:Antigens, CD; D003520:Cyclophosphamide; D004317:Doxorubicin; D050835:Interferon Regulatory Factors; D017493:Leukocyte Common Antigens; D011241:Prednisone; D014750:Vincristine; D000099218:Interferon Regulatory Factor-4